Ī��ɳ��, ������ɳ��, �������Է���, �������о�," />
�й�������־ 2009, 34(11) 703- DOI:   1001-8689��2009��11-0703-04  ISSN: 0412-1961 CN: 21-1139/TG

����Ŀ¼ | ����Ŀ¼ | ����� | �߼�����                                                            [��ӡ��ҳ]   [�ر�]
����
��չ����
������Ϣ
Supporting info
PDF(264KB)
[HTMLȫ��]
�����PDF
�����
�����뷴��
�ѱ����Ƽ������� Ī��ɳ��| ������ɳ��| �������Է���| �������о�

����ƪ�����£��������Ƽ��������������ַ��" name=neirong>
�����ҵ����
�������ù�����
����
Email Alert
���·���
���������Ϣ
���Ĺؼ���������
Ī��ɳ��zz')" href="#">Ī��ɳ��
������ɳ��
�������Է���
�������о�
���������������
���??
������
����
����
��ʫ??
����֥
PubMed
Article by Yang, H. F.
Article by Liu, D. M.
Article by S. N.
Article by W. Z.
Article by Song, S. D.
Article by Hu, W. Z.
Ī��ɳ����������ɳ�������������Է��׵��������о�
���ҽ�ƴ�ѧ�ڶ�ҽԺ��Ⱦ��,���300211
ժҪ��

Ŀ������Ī��ɳ��ע��Һ��������ɳ��ע��Һ�������������Է����е��ٴ���Ч�Ͱ�ȫ�ԡ�����������������š�����ҩ����յ��о�������������ƽ����d7��PP������������Ͷ�������ٴ���Ч�ʷֱ�Ϊ97��0����92��1����ϸ������ʣ�PP��MBE��������ֱ�Ϊ96��0����96��7������ȫ�Է�����������Ͷ�����IJ�����Ӧ�����ʾ�Ϊ20�����������ͳ��ѧ��������ȽϾ��������Բ��죨P��0��05��������Ī��ɳ��ע��Һ��������ɳ��ע��Һ�����������Է��װ�ȫ����Ч��

�ؼ���� Ī��ɳ��zz')" href="#"> Ī��ɳ��   ������ɳ��   �������Է���   �������о�  
Randomized controlled clinical trial of moxifloxacin versus levofloxacin in the treatment of community acquired pneumonia
Department of Infection Diseases,Second Hospital of Tianjin Medical University, Tianjin 300211
Abstract:

Objective To evaluate the efficacy and safety of moxifloxacin for the treatment of the patients with community acquired pneumonia. Methods A randomized controlled, parallel, block, open clinical trial was conducted. Patients were randomly divided into groups. Results The overall efficacy rates in PP were 97.0% and 92.1% , respectively. The bacterial eradication rates of each group in PP/MBE were 96.0% and 96.7% , respectively. The adverse drug reaction rates, which related to study drug of each group were 20%. The results showed that there were no statistical differences between these two groups �� P �� 0.05 ��. Conclusion Moxifloxacin was effective and safe as levofloxacin in the treatment of community acquired pneumonia.

Keywords: Moxifloxacin   Levofloxacin   Community acquired pneumonia   Randomized controlled trials  
�ո����� 2009-06-14 �޻�����  ����淢������  
DOI: 1001-8689��2009��11-0703-04
�����Ŀ:

ͨѶ����:
���߼��: ��ݷң�Ů������1965�꣬˶ʿ��������ҽʦ�����¸�Ⱦ����ʪ��רҵ�о���
����Email:

�ο����ף�
�������������

Copyright by �й�������־